AMC is about to go bankrupt just like the DCVax trial was said to never be completed or results would never be published in a reputable journal, lol.

https://www.reuters.com/legal/us-prosecutor-who-targeted-spoofing-misconduct-leaves-doj-2023-10-23/

Is that all NWBO did... " go into silence mode "?

I understand. I ignored the factors you mentioned just like NWBO naysayers ignore so many factors with regard NWBO to focus solely on pps!

quote]Look at the years 1981 through 1985, there were many days where Apple's pps opened and/or closed under $1. Your statement actually proves my point: The PPS at a given point in time cannot be the sole variable one looks at in examining the investment value of a company. Thank you. You rightly included stock splits and multiplier. It is appropriate to state those facts. But Mr. moderator, why won't you comment on the variables naysayers intentionally ignore with this same vigor? Your vigor is misplaced. Does it reveal you true stance on NWBO?

Funny how NWBO naysayers harp solely on the .30 pps of a pre-market company but absolutely ignore the efficacy of DCVax (the ONLY real treatment for all tumor-based cancers), automated/infinitely scalable manufacturing, protective patents, and demand that will be insatiable, once DCVax is approved. Some of these naysayers will actually (and foolishly) deny these points.[/quote]

Manibiotech, do you really believe short attacks can be avoided by reading and implementing the concepts in this document? There is no Wall-street cop on the beat. The SEC has no teeth, so no bite, to serve as a deterrent to wall-street fraud and other malfeasance. FINRA governing body consists of the worst of wall-street fraudsters (hence, citadel's $1 million fine to 10 billion unreported order/option events)! The DOJ is totally impotent and has been for decades! Hell, the lead DOJ attorney in charge of investigating naked short selling recently quit and joined the Citadel team!

Without a cop on the wall-street beat to met out consequences to the fraudsters, no strategy will work. Just look and AMC, GNS, NWBO! Hell the SEC and FINRA made MMTLP disappear and stole investors' $$$ in broad day light under the watch of the DOJ. When Congressional oversight committee members asked for the bluesheet data, FINRA literally told them to go f... themselve! What did they do? Nothing.

What does this tell you: Wall-street is in total control at the moment (but I believe the tide is turning)!

Look at the years 1981 through 1985, there were many days where Apple's pps opened and/or closed under $1. Your statement actually proves my point: The PPS at a given point in time cannot be the sole variable one looks at in examining the investment value of a company. Thank you. You rightly included stock splits and multiplier. It is appropriate to state those facts. But Mr. moderator, why won't you comment on the variables naysayers intentionally ignore with this same vigor? Your vigor is misplaced. Does it reveal you true stance on NWBO?

Funny how NWBO naysayers harp solely on the .30 pps of a pre-market company but absolutely ignore the efficacy of DCVax (the ONLY real treatment for all tumor-based cancers), automated/infinitely scalable manufacturing, protective patents, and demand that will be insatiable, once DCVax is approved. Some of these naysayers will actually (and foolishly) deny these points.

"The old Apple comparison" indeed as you are the one who singularly focus on NWBO's pps 24/7/365. I thought by showing you other stocks who had penny stock-status fared might illustrate the absurdity in that singular focus. LOL, now you bring up

Why do you think it would be difficult for NWBO to make a lucrative deal with a bp? BP's, the way I see it, don't/won't have a choice.

1. DCVax is the most effective single treatment against cancer succeeded only by DCVax + PDl1 + Poly-ICLC.
2. DCVax will become SOC for all tumor-based cancers.
3. Automated manufacturing/scalability is close to completion.
4. NWBO will have world-wide combo patent.
5. Dendritic cell manipulation/maturation is on lock-down via NWBO/Roswell patents!

Manibiotech, do you disagree with any of the above 5 points... just curious?

For much of the time from 1981 to around 1985, Apple's stock was under 60 cents. Did Apple investor's stupidity look good back then too?

DCVax works. Full automation is ready. MHRA approval is imminent. DCVax will be SOC for all tumor-based cancers. Combo drugs increase efficaciousness SIGNIFICANTLY. NWBO is very close to a world-wide combo-patent and they have dendritic cell maturation, manipulation and production on lockdown via patents.

Who gives a damn what the pps is now? You see what is happening.

I love you posts by the way, lol.

You are wrong.

First, comparing the bespoke, groundbreaking DCVax platform to a standardized, one-size-fits-all drug is flawed. They are worlds apart and cannot be assessed by the same criteria. It's like trying to wear a glove that just doesn’t fit.

Second, it seems you've overlooked the potential of DCVax to become the universal treatment for all tumor-based cancers.

Third, considering DCVax’s highly personalized and effective nature, wouldn't a franchise model be more advantageous? It could foster much more competition, benefiting patients, the industry, shareholders, and NWBO itself, rather than letting a single pharmaceutical giant monopolize it.

The stock price at a given moment of time, particularly in the case of a pre-revenue biotech, means nothing. Today's pps will move after MHRA approval, and automated manufacturing is fully in place. Netflix, Apple, Amazon, and a host of other stocks were penny stocks too... and people, just like you, were blogging about how the stocks would never be of any value due to the pps at the time. Remember Dell... when no one believed people would buy PCs online, lol?

Here's what naysayers cannot deny: If DCVax works (and we all KNOW that it does) and if its production can be damn near fully automated (and we all KNOW, via Flaskworks, it can be) and other drugs in combo with DCVax-- by the way, NWBO is close to worldwide combo patent-- significantly increase efficacy against ALL Cancers (and we KNOW this to be true), even a caveman can see what's coming.

I suggest that you too sees what's coming... which explains your 24/7/365 desperation-posting.

Carry on.

Correct, LP has a history of pulling out a spectacularly positive and unexpected surprise every now and again. Remember Flaskworks, the Huawei land deal and the recent Roswell Park collaborations? Stay tuned.

Hear! Hear!

Dang!!! I wish I could.....

Hear! Hear!

Point taken.

Technically, you are correct. But if the "abandoned" applications were replaced/upgraded with a continuation patent application, then the combo patent is still being pursued. In my mind, "still being pursued via a continuation patent application" is similar to "not abandoned". Perhaps "NWBO patents are still being pursued" would have been more accurate.

Thanks for the correction. I don't want to confuse anyone.

Thank you so much for the info, CrashOverride. Indeed, the US combo patent has not been abandoned!

Thanks Flipper...

Is NWBO no longer applying for a combo patent in the U.S.? I know NWBO was granted a combo patent in Europe but regarding the U.S., patent applications 14/534158 and 14/433879 have been abandoned. I thought 14/433879 was re-filed. Does anyone have any info?

U.S. COMBO PATENT APPLICATION 1:


U.S. COMBO PATENT APPLICATION 2:


EUROPEAN COMBO PATENT:

Wishful thinking...

Technically correct, it is more than that.

However, the deferred prosecution agreement with the U.S. Department of Justice (DOJ) essentially removes the ONLY disincentive that could curtail Wall Street's malfeasance: Imprisonment and removal or suspension of financial licensing!

The only way, IMHO, the deferred prosecution agreement could be a deterrent is if the DOJ is going after the biggest fish (say, Citadel) and the defendant has relevant detailed knowledge and, as a condition of the deferred prosecution agreement, agrees to cooperate with ongoing investigations (this may be what is happening). Otherwise, the defendant just pays fines, usually significantly less than the $ profited, and escapes with no charges, criminal record, or impact to his ability to continue working on Wall Street or any real disincentive at all. Just my 2 cents (though no one asked).

My bad...

That’s beyond my expertise, but here’s my take: Taking NWBO private now would mean missing out on a significant payday, especially when NWBO has the market makers and short sellers cornered (i.e. by the balls, lol) and is on the brink of approval from a top-tier regulatory agency. Considering the costs NWBO has incurred to reach this point (due to having to raise funds during periods of spoofing and naked shorting) taking it private now would be like betting on a 100-1 horse and tearing up the ticket just before it crosses the finish line in first place.

The upcoming catalysts for NWBO— MHRA approval, collaborations and partnerships, global combination patents, automated, infinitely scalable manufacturing and insatiable worldwide demand for all tumor-based cancers —are inevitable. NWBO is about to get P.A.I.D!

I'm grasping at straws?!?!?! ROTFLMAO You can't make this shit!

You do realize, the 9/30 date was not rendered from a prophet uttering the inerrant words of all-knowing God. It was an estimate, based on the interpretation of numerous variables and expected events occurring on a specific timeline.

It is rather telling that despite a Journal Article with 73 Coauthors indicating that Statistical Significance was achieved, you continue to attack the DCVax-L trial. But yet you tout how MesoPher's "results got published in most prestigious oncology journal". Was JAMA not a "most prestigious oncology journal" when it peer-reviewed DCVax-L or just when it reviewed MesoPher's open label study?

Don't you find it bizarre that you reject the NYAS, JAM, ASCO and a number of other organizations findings/presentations but tout MesoPher which hasn't even started a phase ii/iii trial yet.

Are you a frustrated long or a stone-cold basher masquerading as a frustrated long? Inquiring longs want to know...

So, if DCVax-L get approval in October, they article is "a lie"?

The DCVax-L platform is like nothing we've ever seen. We are looking at a once-in-a-lifetime transformation starting with the treatment of GBM ultimately defeating all cancers (and beyond). Legacy fortunes are about to be lost or gained. The status quo will fight to the death to prevent this transformation.

They should have killed NWBO before they completed the trial, patented the product/process and implemented automated manufacturing. They tried but failed. They lost. They can no longer stop NWBO/DCVax. They can frustrate longs, cause delays and anxiety but they cannot stop DCVax-L's rise.

Know What You Hold. Stay encouraged.

Hear! Hear!

Manibiotech, do you think NWBO did a needless, 20-year "drag along" with DCVax. You don't think part of the time was necessitated by the international clinical trial, the desire to wait to demonstrate long-tail survival, to influence and allow the FDA to make the necessary guideline chances in order to fairly, accurately review the Trial/SAP, the creation of manufacturing and now flaskworks?

NWBO was not whistling dixie for 20 years. LP and team busted their asses to get here. Don't you think they deserve some credit?

I agree. I try to have some grace and mercy for those longs who have been here 12 years. They may bash out of frustration, but a few aren't bashers. But to the true bashers... to hell with them!

I don't remember that, and I must admit I am disappointed it hasn't happened yet. But LP and the team are the only ones who have all of the variables needed to make the decision as to when to proceed or not. We are closer than we have ever been. I am excited!

Amphera hasn't started the phase II/III yet. They haven't automated the training or production of Dendritic cells. How can they possibly get approval and commercialize first? They can't.

Regarding the timing... anytime one has a disruptive product that threatens a transformational shift, challenging the corporate status quo, one must expect a fight for one's very survival.

Given the 1.7 million page submission to the MHRA, I would suggest that the info required by the FDA is included so 90%+ of the work necessary for FDA submittal is done. In fact, CEO Powers alluded to this in the Oct 13 2023 press release:

Lol... I just don't see how Amphera can get MesoPher approval, efficiently produce (i.e., automate its manufacturing) and distribute the product before NWBO does, given that it hasn't even started its phase II/II trial.

Yes, it did:

According to the Amphera website ("pipline" page), the completed phase II pancreatic REACTIVE phase II trial was described as "an open label phase II study". I also confirmed that Amphere is now preparing a randomized phase II/III trial to replicate this efficacy signal. So it seems that Amphera still has a ways to go since it hasn't started its phase II/III yet...

You are correct. The Copilot AI quote I posted was incorrect. The accurate info is included in my response to your correction:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175155297

You are correct. The quote I posted from the copilot AI was incorrect. Thanks for pointing that out. Copilot originally ai stated:

Many treatments can "seem" better at the preclinical stage...